INBIRS   24491
INSTITUTO DE INVESTIGACIONES BIOMEDICAS EN RETROVIRUS Y SIDA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
COMPARISON OF HUMAN T CELL LEUKEMIA VIRUS-1/2 (HTLV-1/2) SCREENING ASSAYS IN SOUTH AMERICA: IMPLICATIONS IN THE LOSS OF BLOOD UNITS
Autor/es:
GABRIELA PATACCINE; CAMILA CANEPA; JORGELINA BLEJER; ADRIANA ALTER; WILLIAMS PEDROZO; RICHARD MALAN; MARCELO BORDA; CECILIA DELFINO; MIRNA BIGLIONE; CAROLINA BERINI
Reunión:
Congreso; International Conference in Retrovirus and HTLV; 2013
Resumen:
Although the detection of HTLV antibodies became
mandatory in Argentinean blood banks since 2005, there is no recommendation on
how to perform the screening. As a consequence, there is a variable number of
HTLV false positives depending on the kit used. The aim of the
present study was to evaluate the performance of six commercial screening tests
available currently for the initial diagnosis of HTLV-1/2 infection in South
America. The positive panel included 14 HTLV-1 and 13 HTLV-2
samples confirmed by WB (HTLV-1/2 MP Diagnostics). The negative panel included 233
samples analysed with Architect (n=47), Diapro (n=46), MP (n=45), Murex (n=47)
and Serodia (n=48), collected in 5 different institutions in a period of one up
to 10 consecutive days. All of them were confirmed by n-PCR. The sensitivity
for all HTLV diagnostic kits was 100.0%. The most
specific test was Serodia (PA) (99,1%; 2/233), followed by the ELISAs: Celquest
(98.3%, 4/233), Murex (97.8%; 5/233), MP and Architect (97.4%; 6/233), and
Diapro (93,1%; 16/233). According to this data, 2 to 16 blood units out of 233
should have been discarded due to false positive results in a period of 10 days.
This data must be considered when choosing the assays,
not only to obtain an optimal efficiency on HTLV-1/2
diagnosis, to increase the number of potential blood units and to decrease the circulation of anxious individuals
without a final result, but also to lower the overall cost-benefits of the diagnosis
in the health care system.